News articles about Compugen (NASDAQ:CGEN) have trended somewhat negative on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Compugen earned a news sentiment score of 0.00 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.7070519134226 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Compugen (NASDAQ CGEN) opened at $3.00 on Friday. Compugen has a 12 month low of $2.25 and a 12 month high of $5.40.
Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.19) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.19). analysts expect that Compugen will post -0.73 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on CGEN. Zacks Investment Research raised shares of Compugen from a “sell” rating to a “hold” rating in a research note on Tuesday, October 3rd. ValuEngine cut shares of Compugen from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/01/21/somewhat-critical-news-coverage-somewhat-unlikely-to-affect-compugen-cgen-share-price.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.